Triptorelin (Trelstar / Triptodur / Decapeptyl / Diphereline)
Triptorelin pamoate; also available as triptorelin acetate. Chemical name: 5-oxo-L-prolyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-D-tryptophyl-L-leucyl-L-arginyl-L-prolylglycine amide. Synonyms: triptoreline, D-Trp-6-LHRH, [D-Trp6]-GnRH.
Approved status applies to specific products, routes, and indications, not every use context discussed online.
An FDA-approved injection that temporarily suppresses sex hormone production, used for advanced prostate cancer and central precocious puberty (abnormally early puberty) in children. The effect is fully reversible when treatment stops.
Safety Summary
Triptorelin's adverse effect profile is predominantly mechanism-related, driven by sustained suppression of gonadal sex steroids, and is shared across the GnRH agonist drug class. The FDA label includes warnings for: tumor flare (first 2-4 weeks), cardiovascular events with ADT, QT/QTc prolongation risk with co-administered QT-prolonging drugs, hyperglycemia/diabetes, and progressive bone loss. Rare serious events (SJS/TEN, seizures, pseudotumor cerebri) documented through post-marketing surveillance and updated in 2025 FDA label. A 2025 FAERS pharmacovigilance analysis (PMC12402341) identified neuropsychiatric/behavioral safety signals (hypothesis-generating, not causal). No evidence of tolerance/tachyphylaxis with chronic use. Immunogenicity appears low. No consistent de novo malignancy signal. No CYP-mediated drug interactions; interactions are pharmacodynamic (QT-prolonging drugs, other GnRH agonists, antidiabetics). Pediatric BMD effects are predominantly reversible after discontinuation.
Clinical check-in
If real-world use or exposure is being considered, review potential interactions, contraindications, and monitoring needs with a licensed clinician rather than relying on summary copy alone.
Sources: [1-11]